151 related articles for article (PubMed ID: 28799818)
21. Programmed death ligand 1 expression and CD8
Zhou J; Gong Z; Jia Q; Wu Y; Yang ZZ; Zhu B
Biochem Biophys Res Commun; 2018 Apr; 498(4):751-757. PubMed ID: 29526752
[TBL] [Abstract][Full Text] [Related]
22. [Comparative study for detecting micrometastases of lymph nodes in patients with lung cancer].
Wang YX; Sun YE; Li XH; Wang ZB; Liu YL; Chen LA; Tong XY
Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(1):19-21. PubMed ID: 18346373
[TBL] [Abstract][Full Text] [Related]
23. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
24. PD-L1
Raniszewska A; Vroman H; Dumoulin D; Cornelissen R; Aerts JGJV; Domagała-Kulawik J
Cancer Immunol Immunother; 2021 Feb; 70(2):453-461. PubMed ID: 32808188
[TBL] [Abstract][Full Text] [Related]
25. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages.
Vieira T; Antoine M; Hamard C; Fallet V; Duruisseaux M; Rabbe N; Rodenas A; Cadranel J; Wislez M
Lung Cancer; 2016 Aug; 98():51-58. PubMed ID: 27393506
[TBL] [Abstract][Full Text] [Related]
26. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer.
Mao Y; Li W; Chen K; Xie Y; Liu Q; Yao M; Duan W; Zhou X; Liang R; Tao M
Oncotarget; 2015 Feb; 6(5):3452-61. PubMed ID: 25609202
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of CCR7 mRNA in nonsmall cell lung cancer: correlation with lymph node metastasis.
Takanami I
Int J Cancer; 2003 Jun; 105(2):186-9. PubMed ID: 12673677
[TBL] [Abstract][Full Text] [Related]
28. Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer.
Sheffield BS; Fulton R; Kalloger SE; Milne K; Geller G; Jones M; Jacquemont C; Zachara S; Zhao E; Pleasance E; Laskin J; Jones SJ; Marra MA; Yip S; Nelson BH; Gown AM; Ho C; Ionescu DN
J Histochem Cytochem; 2016 Oct; 64(10):587-600. PubMed ID: 27591097
[TBL] [Abstract][Full Text] [Related]
29. [Risk factor analysis of mediastinal lymph node metastasis in non-small cell lung cancer patients and the strategy of mediastinoscopy prior to surgery].
Wang X; Zheng L; Zhang SY; Xie ZM; Yu H; Su XD; Wang JY; Huang ZF; Yang MT; Rong TH
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):456-9. PubMed ID: 19950559
[TBL] [Abstract][Full Text] [Related]
30. Nuclear expression of CXCR4 in tumor cells of non-small cell lung cancer is correlated with lymph node metastasis.
Na IK; Scheibenbogen C; Adam C; Stroux A; Ghadjar P; Thiel E; Keilholz U; Coupland SE
Hum Pathol; 2008 Dec; 39(12):1751-5. PubMed ID: 18701133
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer.
Passlick B; Izbicki JR; Kubuschok B; Nathrath W; Thetter O; Pichlmeier U; Schweiberer L; Riethmüller G; Pantel K
J Clin Oncol; 1994 Sep; 12(9):1827-32. PubMed ID: 8083707
[TBL] [Abstract][Full Text] [Related]
32. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.
Calles A; Liao X; Sholl LM; Rodig SJ; Freeman GJ; Butaney M; Lydon C; Dahlberg SE; Hodi FS; Oxnard GR; Jackman DM; Jänne PA
J Thorac Oncol; 2015 Dec; 10(12):1726-35. PubMed ID: 26473645
[TBL] [Abstract][Full Text] [Related]
33. [Clinical pathological study on nodal micrometastases of non-small-cell lung cancer].
Wang YX; Chu XY; Sun YE; Wang ZB; Li XH; Zhang GK
Zhonghua Wai Ke Za Zhi; 2007 Jan; 45(2):114-7. PubMed ID: 17418040
[TBL] [Abstract][Full Text] [Related]
34. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression.
Konishi J; Yamazaki K; Azuma M; Kinoshita I; Dosaka-Akita H; Nishimura M
Clin Cancer Res; 2004 Aug; 10(15):5094-100. PubMed ID: 15297412
[TBL] [Abstract][Full Text] [Related]
35. Use of maximum standardized uptake value on fluorodeoxyglucose positron-emission tomography in predicting lymph node involvement in patients with primary non-small cell lung cancer.
Muto J; Hida Y; Kaga K; Ohtaka K; Okamoto S; Tamaki N; Nakada-Kubota R; Hirano S; Matsui Y
Anticancer Res; 2014 Feb; 34(2):805-10. PubMed ID: 24511016
[TBL] [Abstract][Full Text] [Related]
36. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients.
Djenidi F; Adam J; Goubar A; Durgeau A; Meurice G; de Montpréville V; Validire P; Besse B; Mami-Chouaib F
J Immunol; 2015 Apr; 194(7):3475-86. PubMed ID: 25725111
[TBL] [Abstract][Full Text] [Related]
37. Cytokeratin 19, carcinoembryonic antigen, and epithelial cell adhesion molecule detect lung cancer lymph node metastasis in endobronchial ultrasound-guided transbronchial aspiration samples.
Bugalho A; Martins C; Dias SS; Nunes G; Silva Z; Correia M; Marques Gomes MJ; Videira PA
Clin Lung Cancer; 2013 Nov; 14(6):704-12. PubMed ID: 23886796
[TBL] [Abstract][Full Text] [Related]
38. Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society.
Sholl LM; Aisner DL; Allen TC; Beasley MB; Borczuk AC; Cagle PT; Capelozzi V; Dacic S; Hariri L; Kerr KM; Lantuejoul S; Mino-Kenudson M; Raparia K; Rekhtman N; Roy-Chowdhuri S; Thunnissen E; Tsao MS; Yatabe Y;
Arch Pathol Lab Med; 2016 Apr; 140(4):341-4. PubMed ID: 26780537
[TBL] [Abstract][Full Text] [Related]
39. Expression of CXCR4 and VEGF-C is correlated with lymph node metastasis in non-small cell lung cancer.
Bi MM; Shang B; Wang Z; Chen G
Thorac Cancer; 2017 Nov; 8(6):634-641. PubMed ID: 28925100
[TBL] [Abstract][Full Text] [Related]
40. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
